

Review Article

Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer's disease

Weiwei Yu, Haiqiang Jin and  Yining Huang

Department of Neurology, Peking University First Hospital, 8 Xishiku Street Xicheng District, Beijing, China 100034

Correspondence: Yining Huang (ynhuang@bjmu.edu.cn)



Alzheimer's disease (AD), a progressive neurodegenerative disorder, is a leading global health concern for individuals and society. However, the potential mechanisms underlying the pathogenesis of AD have not yet been elucidated. Currently, the most widely acknowledged hypothesis is amyloid cascade owing to the brain characteristics of AD patients, including great quantities of extracellular β -amyloid ($A\beta$) plaques and intracellular neurofibrillary tangles (NFTs). Nevertheless, the amyloid cascade hypothesis cannot address certain pathologies that precede $A\beta$ deposition and NFTs formation in AD, such as aberrant calcium homeostasis, abnormal lipid metabolism, mitochondrial dysfunction and autophagy. Notably, these earlier pathologies are closely associated with mitochondria-associated membranes (MAMs), the physical structures connecting the endoplasmic reticulum (ER) and mitochondria, which mediate the communication between these two organelles. It is plausible that MAMs might be involved in a critical step in the cascade of earlier events, ultimately inducing neurodegeneration in AD. In this review, we focus on the role of MAMs in the regulation of AD pathologies and the potential molecular mechanisms related to MAM-mediated pathological changes in AD. An enhanced recognition of the preclinical pathogenesis in AD could provide new therapeutic strategies, shifting the modality from treatment to prevention.

Introduction

Alzheimer's disease (AD) is recognized as a global public health priority by the World Health Organization and is the major cause of dementia, accounting for 50–75% of 44 million people the world over suffering from dementia in 2014 [1]. Advancing age is considered as the primary risk factor for AD. Therefore, it is estimated that this number will be more than triple by 2050 due to the rapid growth of the population over 65, and that the annual expense of just dementia in the USA alone will exceed \$600 billions [2]. Other AD risk factor include diabetes, hypertension, traumatic brain injury and clinical depression, all of which are believed to render neurons vulnerable to AD via accelerating neuronal energy deficits and enhancing the oxidative stress, are also considered as risk factors for AD [3]. AD, characterized by progressive neuronal loss in the cortex and hippocampus, is primarily manifested as the gradual and irreversible loss of memory and impairment of cognitive function, even the more severe behavioral symptoms that affect the ability to function in daily life [4,5]. AD can develop in both sporadic and familial forms, with the vast majority of AD possessing an apparently sporadic basis. So far, autosomal dominant mutations related to familial AD (FAD) have been identified in three genes: amyloid precursor protein (*APP*), presenilin 1 (*PSEN1*) and presenilin 2 (*PSEN2*). These genes account only for a minute (<0.5%) proportion of FAD [1]. Generally, the onset age of FAD in individuals who inherit a mutation in any of the three genes (*APP*, *PSEN1* and/or *PSEN2*) is earlier than sporadic AD (SAD) individuals, typically between their third to fifth decades of life

Received: 17 June 2020
 Revised: 02 October 2020
 Accepted: 19 October 2020

Version of Record published:
 06 January 2021




Figure 1. The amyloid cascade hypothesis

(1) Non-amyloidogenic pathway: Full-length APP is first cleaved by α -secretase to release sAPP α from the cell membrane and retain C83. C83 is subsequently processed by γ -secretase to produce P3 and AICD, which are shifted toward the nucleus to regulate Ca^{2+} -related gene expression. (2) Extracellular amyloidogenic pathway: APP can also be cleaved by BACE1 in amyloidogenic processing to produce sAPP β and C99. Subsequent cleavage of C99 by γ -secretase produces A β 42/40. Mutations that occur in *PSEN1*, *PSEN2* and *APP* genes can increase the rate of proteolysis of APP by BACE1 and transform the cleavage position of A β region by γ -secretase, leading to an increased ratio of A β 42/40. (3) Intracellular amyloidogenic pathway: C99 can translocate to endosomes and be cleaved by γ -secretase to generate intracellular A β , which promotes the NFTs formation via activating the intracellular Ca^{2+} (Ca_i^{2+}) and extracellular A β deposition. Both extracellular A β deposition and intracellular NFTs lead to neuronal dysfunction and death; APP, amyloid precursor protein; BACE1, β -secretase; A β , β -amyloid; AICD, APP intracellular domain; PSEN1, presenilin 1; PSEN2, presenilin 2; NFTs, neurofibrillary tangles; AD, Alzheimer's disease.

[6,7]. Regrettably, despite the fact that substantial effort has been invested in understanding AD pathogenesis since the first case was reported in 1907 [8], the exact mechanism underlying the pathophysiology and pathogenesis of AD still remain a mystery and no curative treatment for this disease has yet been developed.

Amyloid cascade

The cardinal positive pathologies of AD are the extracellular accumulation of amyloid plaques mainly composed of β -amyloid (A β) and intracellular neurofibrillary tangles (NFTs) containing numerous hyper-phosphorylated tau [9], simultaneously accompanied by astrogliosis and microglial activations [10,11]. Based on the major pathological hallmarks in AD patients' brain, Hardy and Higgins first proposed the amyloid cascade hypothesis in 1992 [12], which has become the most generally-accepted pathogenetic hypothesis of AD [13]. A β is a self-aggregating peptide containing 40–42 amino acids that is generated by the proteolytic processing of APP, a ubiquitous glycoprotein generally expressed in the whole brain. Full-length APP (700 amino acids) is composed of a large transmembrane N-terminal ectodomain including the A β sequence and a short intracellular C-terminal domain [14]. APP proteolytic processing occurs via three pathways (Figure 1): (1) The non-amyloidogenic pathway. APP is first cleaved by α -secretase at residues adjacent to the transmembrane domain to produce a large N-terminal fragment (NTF), sAPP α and a

short membrane-bound C-terminal fragment (CTF) containing 83 amino acids (C83). C83 is subsequently cleaved at the lipid bilayer by γ -secretase complex to produce a non-amyloidogenic peptide denominated P3 and the APP intracellular domain (AICD), which can be localized to the nucleus to regulate gene expression [15]. (2) The extracellular amyloidogenic pathway. APP is first cleaved of by β -secretase (BACE1), leading to the secretion of sAPP β NTF and the membrane-tethered 99 amino acids (C99). C99 is then cleaved by γ -secretase to generate the extracellular A β as well as AICD. (3) The intracellular amyloidogenic pathway. An alternative route for the C99 generated as in the above amyloidogenic pathway, C99 can also be cleaved by γ -secretase in endosomes to form intracellular A β , which accelerates NFTs formation via activating intracellular Ca²⁺ (Ca_i²⁺) and extracellular A β deposition. The specific cleavage site of γ -secretase plays an essential role in determining the aggregation and toxicity of the A β peptide. A β 42 (containing 42 amino acids) possesses the more toxicity and aggregation than A β 40 (40 amino acids) and prefers to deposit in vulnerable brain regions primarily related to learning, memory and emotional behaviors such as the entorhinal cortex, hippocampus, inferior parietal cortex and basal forebrain due to its higher rate of fibrillization and insolubility [16]. Additionally, A β 40 appears to be mostly identified in non-neuronal cells such as cerebral vessels [17]. By analyzing the total A β in 27 AD brains, Gravina et al. revealed that the quantity of A β 42 in AD brains with minimal congophilic angiopathy and minor A β 40 were equivalent to brains with substantial congophilic angiopathy and plentiful A β 40, demonstrating that A β 42 deposition in plaques is critically important for AD pathogenesis with additional deposition of A β 40 [18]. Their work indicated that the increased ratio of A β 42/40, rather than the total A β , is the exact cause for AD. The transmembrane proteins PSEN1/2 comprise the catalytic subunit of γ -secretase [19]. Significant mutations in *APP* or/and *PSEN1/2* might lead to the excessive generation of A β 42 and the increased ratio of A β 42/40 [20]. The serial processes resulting in the A β deposition are named 'amyloid cascade'. The A β deposition leads to the progressive neuronal loss in the vulnerable brain regions due to its direct toxic effects on neurons as well as its indirect effects of greatly increasing the vulnerability of neurons to oxidative stress and excitotoxicity, ultimately causing a neurodegenerative disorder [21]. Notably, tau protein in normal brains has an important effect on microtubule stabilization, axonal transport and neurogenesis [22]. However, the high level of phosphorylated tau protein that assemble into paired helical filaments can disturb the physiological activity and aggravate neurotoxicity, which finally leads to apoptosis via interacting with A β [23,24].

The amyloid cascade hypothesis consociates many different AD discoveries and explains why mutations in *APP* and *PSEN1/2* result in this disease, making it a persuasive argument. Nevertheless, FAD cases account for only a small percent of all AD individuals and the amyloid cascade hypothesis does not explain the other various features of AD including aberrant calcium homeostasis [16], altered cholesterol and phospholipid metabolism [25,26], mitochondrial dysfunction [27] and autophagy, all of which emerge before the appearance of plaques and tangles but are ostensibly unrelated to the formation of plaques and tangles. Therefore, there may be other cellular mechanisms of mediating A β metabolism involved in the AD pathophysiology. Coincidentally, the earlier pathological events of AD are functions concerning to the mitochondria-associated membranes (MAMs), indicating that there is a great possibility that perturbed MAMs functions may be involved in the AD pathogenesis.

MAMs

The multiple biological procedures that are essential for maintaining homeostasis in eukaryotic cells are effectively performed via the compartmentalization of specific biochemical reactions to the corresponding membrane-bound organelles, which fulfills the requirements of transferring many necessary metabolites and signaling molecules between organelles [28]. While the role of the cell membrane in vesicle transport and transcriptional pathways has been well studied, there has been an increase in research focusing on the physical interaction between the endoplasmic reticulum (ER) and mitochondria, referred to as the MAMs. The concept that there is a relationship between the ER and mitochondria was first proposed in the 1960s [29], although the initial morphological evidence for the physical interaction between the ER and mitochondria via an electron microscope did not emerge until the early 1990s [30]. Structurally, MAMs can fluctuate dynamically as they are the highly fluid membranes composed of phospholipids [31]. The distance between the ER and mitochondria contact sites has been measured to be between 10 and 30 nm wide [32]. The closely apposed membranes are sufficient to demonstrate that MAMs are not fusions of membranes but utilizations of proteinaceous tethers, which provide direct, fast, and reciprocal signaling molecules transport between the two compartments [33]. Zhang et al. were the first group to analyzed the MAMs' proteome in the 'heavy' MAMs fraction isolated at lower centrifugal forces rather than the previously standard MAMs isolation measures and identified 991 proteins in this 'heavy' MAMs fraction [34]. Afterwards, Poston et al. revealed that there are 1212 high confidence proteins containing weak soluble proteins presenting in brain MAMs [35]. The close gap between the ER

and the mitochondria contains numerous proteins and plays a critical role in many crucial metabolic processes, ranging from efficient transfer of calcium [36], phospholipid exchange [37], sterol metabolism, mitochondrial dynamics, autophagy for energy metabolism and even cell survival [38]. Although only a small area of approximately 12% of the outer mitochondrial membrane (OMM) is assessed to interact with the ER [39], this tight ER-mitochondria interaction is extremely stable even when cytoskeletons, including microtubules and intermediate filaments, that are essential for shaping and supporting organelles are undermined [40].



MAMs may play an even more significant role in human neurons, as the distances between the end of axons and the cell body can be up to approximately one meter. The biological procedures in neurons demanding rigorous regulation of both space and time, and have been shown to rely much more on MAMs structures as their particular morphology requirements creates challenges for conventional vesicular transport and transcriptional pathways morphology [41]. Furthermore, emerging evidence exhibits that MAMs are involved in various age-related neurodegenerative disorders, such as AD [42], frontotemporal dementia [43], Parkinson's disease [44] and amyotrophic lateral sclerosis [45,46]. Previous studies of postmortem AD brains have revealed the increased contact sites between the ER and mitochondria and significant expression of MAMs-associated proteins in primary hippocampal neurons [47]. These findings have been validated in the neuronal cells of APP_{Swe/Lon} mice [48]. In this study, the up-regulation of MAMs-associated proteins could be detected in the 2-, 6- and 10-month-old APP_{Swe/Lon} mice, suggesting that pathophysiological changes occurred within 2 month of age and significantly ahead of visible plaques and neurofibrillary tangles. Given this early onset, in our examination we systematically highlight the role of MAMs in early AD and the mechanisms underlying the relation between MAMs signaling and AD.

MAM-mediated intracellular A β deposit in AD

Initial evidence for intracellular A β was provided by Wertkin et al. via observing intracellular A β in a differentiated neuronal cell line [49]. Previous studies have implicated that intracellular A β accumulation induces toxicity in AD [50,51] and that extracellular A β deposits could be secondary to the intracellular A β accumulation [52–54], where the mitochondria accumulation specifically has proven to play a significant role [55]. Mitochondrial A β deposition has been observed in both postmortem AD brains and a transgenic AD mouse model, negatively affecting neuronal functions and ultimately lead to cellular dysfunction [56,57]. Due to the incomplete mitochondrial translocation of APP, it is believed that APP accumulated in the mitochondrial membrane could not be processed to produce A β locally [58]. OMM is the connective site to the ER in MAMs. Previous studies have shown that A β can be imported into the mitochondria through the translocase of the OMM and subsequently localized to the cristae membranes [59]. The γ -secretase enzyme has been reported to be localized not only at the plasma membrane but also at the different subcellular compartments, predominantly at the MAMs. Both A β 40 and A β 42 have been shown to be generated at the MAMs and in immediate proximity to mitochondria [60]. The above findings explain how A β accumulates in mitochondria in AD: MAMs are involved in the generation of intracellular A β , with the OMM serving as the A β transport machinery into mitochondria (Figure 2 (1)). An increase in MAMs may promote mitochondrial A β deposition and their interaction with mitochondrial proteins (Figure 2 (1)). For example, A β can promote reactive oxygen species (ROS) production via binding to the mitochondrial alcohol dehydrogenase (ABAD), ultimately leading to neuronal apoptosis [57]. Additionally, A β impairs the ability of neurons to synthesize adenosine triphosphate (ATP), likely through directly inhibiting the cytochrome *c* oxidase (COX). Neurons with COX deficiency manifest obvious apoptosis, a feature significantly prevalent in AD [61].

MAM-mediated calcium homeostasis in AD

The calcium ion (Ca²⁺) acts as an intracellular messenger and is fundamental for the regulation of various physiological activities in cells. Ca²⁺ mediates a variety signaling pathways and is particularly involved in those related to the dynamic changes of neural circuits, regardless of their structure or function [3]. Ca²⁺ signaling pathways in neurons also play a role in controlling membrane excitability, stimulating the release of neurotransmitters and modulating neuronal biological functions from proliferation, differentiation and apoptosis to gene expression [16]. Factors which all have a connection to how our brains handle received information and stockpile memories [62]. In addition to the Ca²⁺ influx across the plasma membrane through distinct Ca²⁺-permeable channels including voltage-gate Ca²⁺ channel (VGCC), N-methyl-D-aspartic acid (NMDA) receptor, α -amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor and transient receptor potential (TRP) channel, intracellular Ca²⁺ liberated from ER stores via inositol triphosphate receptor (IP3R) triggered by IP3 [63], and ryanodine receptor (RyR) sensitive to ryanodine [64], also have the prominent effects on intracellular Ca²⁺ homeostasis (Figure 3(1)). Enhanced cytosolic Ca²⁺ can also activate IP3R and RyR to trigger the Ca²⁺-induced Ca²⁺ release, enabling the interaction between these two pathways



(3) Unaffected mitochondria

(4) AD affected mitochondria

Figure 2. Mitochondrial alterations related to MAMs in AD

(1) The increased cleavage of C99 by γ -secretase localized at the MAMs promotes A β 42/40 generation, which are subsequently transferred to mitochondria to form mitochondrial A β deposition. A β oligomers can inhibit COX and ABAD functions, increasing the production of ROS and ultimately leading to the apoptosis. (2) C99 generated at the MAMs can affect the lipid composition in the MAMs and augment the mitochondrial ceramide concentration by activating the sphingolipid turnover and hydrolysis, which disturbs the assembly and activity of respiratory supercomplexes, ultimately resulting in bioenergetic deficiencies. (3) The mitochondrial fission can be mediated by proteins DLP1 and FIS1. The OMM fusion is regulated by proteins MFN1 and MFN2 that can form MFN1 and MFN2 homo-oligomeric or hetero-oligomeric complexes while IMM fusion respectively utilizes OPA1. In unaffected mitochondria, the mitochondria with relatively equal morphology are uniformly distributed in the cytosol due to the dynamic equilibrium between the mitochondrial fission and fusion processes. (4) In AD affected mitochondria, augmented mitochondrial fission leads to more fragmented mitochondria that tend to form a 'ring' around the nucleus. MFN2 is also localized at the ER and the ER MFN2 binds to mitochondrial MFN1 and MFN2 increasing the formation of the interconnection between the ER and mitochondria. DLP1, dynamin-like protein 1; FIS1, fission 1; OMM, outer mitochondrial membrane; OPA1, optic atrophy protein 1; IMM, inner mitochondrial matrix; AD, Alzheimer's disease; ER, endoplasmic reticulum; MFN1, Mitofusin-1; MFN2, Mitofusin-2; COX, cytochrome c oxidase; A β , β -amyloid; MAM, Mitochondria-Associated Membrane; APP, amyloid precursor protein; BACE1, β -secretase; ABAD, alcohol dehydrogenase; ATP, adenosine triphosphate.




Figure 3. Ca²⁺ signal transduction and lipid metabolism at the MAMs in AD

(1) Both Ca²⁺ influx through the channels NMDAR, AMPAR and VGCC in the plasma membrane and intracellular Ca²⁺ liberation from ER stores via IP3R and RyR enriched in the MAMs can lead to the toxic amounts of Ca²⁺ in the cytoplasm. (i) IP3R at the MAMs is linked to VDAC1 at the OMM via grp75 in the cytosol and stabilizes itself by binding to Sig-1R at the ER lumen. (ii and iii) The increased Ca²⁺ liberation from IP3R and RyR enhances the postsynaptic responses such as LTD and LTP as well as increases the intracellular A β deposition and NFTs formation. (iv) Meanwhile, high Ca²⁺ levels at the MAMs can promote Ca²⁺ uptake into the mitochondria via triggering the MCU on the IMM. Mitochondrial Ca²⁺ overload will alter the mitochondrial Ca²⁺ signaling causing excessive mtPTP opening, which triggers the cell death signaling cascade. (2) MAMs mediate the lipid transport, synthesis and metabolism in AD. I PS is synthesized in the ER via MAM enzymes, while the conversion of PS to PE via PSD occurs in the mitochondria. Ultimately, PEMT catalyzes methylation of PE to PC in the ER. The enzymes of lipid metabolism are highly compartmentalized at the MAMs, which fosters the synthesis and intermembrane transport of phospholipids. II-III Chol transport and metabolism also utilize the interface between the ER and mitochondria. IV ApoE4 can increase the risk of AD through affecting the MAM-mediated lipid metabolism disorders. MAM, Mitochondria-Associated Membrane; AD, Alzheimer's disease; A β , β -amyloid; NFTs, neurofibrillary tangles; NMDA, N-methyl-D-aspartic acid; AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid; VGCC, voltage-gate Ca²⁺ channel; IP3R, inositol triphosphate receptor; RyR, ryanodine receptor; VDAC1, voltage-dependent anion channel 1; SERCA, sarco-ER calcium-ATPase; Sig-1R, sigma-1 receptor; LTD, long-term depression; LTP, long-term potentiation; mtPTP, mitochondrial permeability transition pore; MCU, mitochondrial Ca²⁺ uniporter; IMM, inner mitochondrial matrix; ER, endoplasmic reticulum; PSD, decarboxylation; PEMT, PE-N-methyltransferase; Chol, cholesterol.

[65]. Additionally, due to the powerful Ca²⁺ buffer function of the mitochondria via the Ca²⁺ uptake mechanisms, the Ca²⁺ content in the mitochondrial matrix can achieve > 10 mM despite its regularly values maintaining as low as 0.1 mM [66]. This capacity for rapid Ca²⁺ influx plays a critical role in neuronal physiology by activating the metabolism and increasing energy productions in the mitochondria [67]. Thereby, both the ER and mitochondria are crucial for maintaining calcium homeostasis [68]. Inadequate intracellular Ca²⁺ can induce neuronal dysfunction, while excessive Ca²⁺ can lead to cell death [69,70].

The calcium hypothesis in AD was initially proposed in 1982 [71], and a milestone consolidated version in 1994 [72]. The expression levels of proteins that are involved in intracellular Ca²⁺ signaling pathways such as IP3R and

RyR have been shown to be significantly altered in brain tissues acquired from AD patients and AD animal models [73,74]. Moreover, increasing evidence has exhibited that MAMs are highly affluent in IP3R [75] and RyR [76]. Even the voltage-dependent anion channel 1 (VDAC1), sarco-ER calcium-ATPase (SERCA) [77] and sigma-1 receptor (Sig-1R) appear to be linked to MAMs [78] (Figure 3(1)). These Ca^{2+} -related proteins in the MAMs rapidly increase the intracellular Ca^{2+} and augment Ca^{2+} uptake into the mitochondria lumen [48,79]. Additionally, mutant PSEN2 has also been shown to have significant impacts on the structural association between the ER and the mitochondria, favoring Ca^{2+} transfer from the ER to mitochondria. Researchers observed that PSEN1 mutations did not induce a similar transformation, despite PSEN1 and PSEN2 being highly homologous [80]. However, this finding is also inconsistent with the observation that PSEN2 mutations are less common than PSEN1 mutations in FAD with a severe clinical course [81]. Additionally, previous researches have shown that PSEN1 mutations heighten the IP3R-mediated calcium trafficking believed to be an MAM-mediated function [3,75]. It is speculated that these two highly homologous proteins induce FAD through the radically different mechanisms. Thus, the conclusion that PSEN2 but not PSEN1 affects MAMs function remains a topic warranting further investigation. Both PSEN1 and PSEN2 mutations have been shown to increase the Ca^{2+} leakage from the ER and decrease the ER Ca^{2+} stores, which would accelerate the Ca^{2+} transfer from the ER to mitochondria and ultimately lead to the mitochondrial Ca^{2+} overload.

How might the perturbed intercellular Ca^{2+} concentration mediated by MAMs bring about neurodegeneration and cognitive deficiency in AD? Based on our examination of the relevant studies we postulate this three mechanism: First, the increased release of Ca^{2+} from the ER stores in presynaptic terminals can undermine synaptic plasticity through consuming the neurotransmitters or enhancing multiple postsynaptic responses such as long-term depression (LTD) and long-term potentiation (LTP) (Figure 3ii) [82], likely leading to a negative impact on the neuronal networks and memory function [83]. Second, the sustained high levels of intracellular Ca^{2+} in neurons can indirectly contribute to neuronal degeneration in AD by promoting the $\text{A}\beta$ deposition and NFTs formation (Figure 3iii). Thirdly, massive mitochondrial Ca^{2+} uptake will alter the mitochondrial Ca^{2+} signaling [84], opening the mitochondrial permeability transition pore (mtPTP) (Figure 3iv). Excessive mtPTP openings allow Ca^{2+} efflux with high conductance from the inner mitochondrial matrix (IMM) lumen, triggering the cell death signaling cascade [85] and ultimately compromising neuronal function and health. Evidence from postmortem analysis of AD brain tissues has revealed increased Ca^{2+} contents in tangle-bearing neurons compared with healthier neurons [86]. This phenom has also been verified in cultured neurons [87,88]. Aberrant Ca^{2+} release from the ER can be inhibited by RyR blockage, finally protecting neurons from the impairment of $\text{A}\beta$ [89]. Meanwhile, $\text{A}\beta$ can also directly induce oxidative stress in neurons, disrupting Ca^{2+} homeostasis and further exacerbating the amyloidogenic procedures of APP [90]. These events ultimately foster a viscous neurodegenerative cycle. The above discoveries indicate that the increased MAMs in AD individuals could explain the altered intracellular Ca^{2+} trafficking through IP3Rs and RyRs [80,91], ultimately resulting in the synaptic dysfunction and neuronal degeneration in AD patients and mice models. However, many questions still remain. How does the PSEN mutations influence the physical and functional contact sites? How would the interaction between the ER and mitochondria contribute to the aberrant intracellular Ca^{2+} in AD. Are other Ca^{2+} -related proteins involved in Ca^{2+} transport from ER to mitochondria in addition to IP3R and RyR? Does Ca^{2+} transport unidirectionally? Further studies related to MAMs in AD cellular and animal models will be necessary to identify the role of MAMs-mediated Ca^{2+} signaling in AD pathogenesis.

MAM-mediated lipid metabolism in AD

Extensive studies have demonstrated that phospholipid synthesis can develop both in the cytoplasm via the Kennedy pathway and in the MAMs through salvaging and recycling [92]. In particular, the latter pathway of phospholipid synthesis has recently garnered significant interest. Mitochondria, as partially autonomous organelles, necessarily rely on the import of specific proteins and lipids to guarantee the cell's structure and survival. The ER, the main 'lipid factory' within the cell, is the source of the majority lipids for being imported into mitochondria. The transport of these lipids necessitates interactions between the two organelles such as specific carrier proteins, membrane contact sites and tethering complexes. MAMs were first conformed to be involved in lipid synthesis by Vance et al. in 1990 [93]. The pathway of phospholipids synthesis mediated by MAMs is a typical communication between the ER and mitochondria (Figure 3I). Phosphatidylserine (PS) is synthesized in the MAMs and subsequently translocated from the ER to mitochondria that is considered to be the rate-determining step in phosphatidylethanolamine (PE) synthesis [94]. Under the action of PS decarboxylase (PSD), the mitochondrially localized enzyme in the IMM, PS transferred to mitochondria is converted into PE. PE is then transmitted back to the ER and ultimately converted into phosphatidylcholine (PC) through the enzyme PE-N-methyltransferase (PEMT) [95]. Remarkably, the levels of both PS and PE, synthesis and transport are significantly elevated in PS-mutant cells, demonstrating that there is increased

ER-mitochondrial communication in the cells [47]. These observations may help explain the abnormal phospholipids metabolism revealed in AD patients.

In addition to phospholipids synthesis, MAMs are also involved in another key function related to the cholesterol metabolism. Newly synthesized cholesterol in the ER also requires transport into the mitochondria for conversion into pregnenolone (Figure 3II), the precursor for steroids, and MAMs play a key role in this rate-limiting step [96]. Furthermore, MAMs have been shown to possess an abundance of cholesterol acyltransferase 1 (ACAT1), which is involved in the conversion of free cholesterol into cholesteryl esters (CEs) (Figure 3III), generally deposited in lipid droplets [97]. Thus, ACAT1 can be used to indirectly measure MAMs activity. Interestingly, significantly higher ACAT1 activity and more lipid droplets containing CEs have been found in PS-mutant fibroblasts compared with control cells [47]. Remarkably, increased MAMs and altered MAMs-mediated lipid homeostasis have also been observed in fibroblasts from FAD patients with an APP mutation and even in fibroblasts from SAD patients [47]. Activated ACAT1 can directly modulate A β formation by regulating the balance between membrane free cholesterol and CEs levels [97,98]. Intriguingly, MAM-mediated lipid synthesis, transport and metabolism can influence the fluidity of the mitochondria membrane and subsequently alter biophysical properties of the membrane environment. The balanced concentration of phospholipids, sterols and sphingolipids seemingly plays an important role in mitochondrial membrane fusion or fission. Thus, two new questions arise: Are MAMs involved in the regulation of lipid transport between the ER and mitochondria? Additionally, can MAM-mediated lipid metabolism in AD affect mitochondrial dynamics and if so, how?

The hypothesis that perturbed MAMs may be involved in the various events of the lipid metabolism in AD patients has been recently strengthened due to the discovery of the effects of apolipoprotein E (APOE) on MAMs [99]. *APOE* gene encodes a component of the lipoproteins named APOE that has the ability to ferry cholesterol and lipids throughout the circulation. The *APOE* gene possesses three variants: ϵ 2, ϵ 3 and ϵ 4. Previous studies have revealed that individuals harboring the ϵ 4 allele are at significantly higher risk for developing SAD than those harboring the common ϵ 3 allele. Compared with non- ϵ 4 carriers, ϵ 4 heterozygotes shows an odds ratio (OR) for AD of \sim 3, even rising to \sim 12 in homozygotes [1]. There is a possibility that ApoE4 plays a key role in mediating MAMs behavior (Figure 3IV). In the brain, APOE is normally not generated in neurons but produced in astrocytes. MAMs activity has been shown to be significantly upregulated in human neuronal-like SH-SY5Y cells and fibroblasts treated with astrocyte-conditioned media (ACM) from human *ApoE4* knock-in mice [99]. Moreover, increased CEs and lipid droplets are observed in ApoE4-ACM-treated cells, implying enhanced cholesterol metabolism at the MAMs [99]. Remarkably, the increase in CEs and phospholipid synthesis were not as statistically significant as in the PS-mutant cells [47], which is compatible with the view that *ApoE4* is not a determinative factor, only a risk factor, for developing AD. Mitofusin-2 (MFN2) localized at the MAMs participates in mitochondrial fusion and its ablation has been shown to decrease the connections between the ER and mitochondria [100,101]. To further verify that increased phospholipid production is indeed intermediated by MAMs, mouse embryonic fibroblasts obtained from *MFN2* knocked-out mice were treated with ApoE4-ACM. The results demonstrated that the abolition of *MFN2* in mouse embryonic fibroblasts led to the down-regulation of the MAMs activity and abrogates the ApoE4-mediated increases in phospholipid synthesis, CEs and cellular lipid droplets [99]. These observations strongly support the view that the ApoE4-mediated effects on phospholipid synthesis and cholesterol metabolism are indeed the results of increased MAMs function. Based on these studies, we propose that altered MAMs behavior can induce the early events in the pathogenesis of AD by participating in lipid transport, synthesis and metabolism.

MAM-mediated mitochondria dysfunction in AD

Over the last few decades, increasing numbers of researchers have focused on the functional impairment of mitochondria in AD. Abundant biochemical evidences has demonstrated that mitochondrial bioenergetic function is clearly attenuated in AD individuals and animal models, characterized by decreased respiratory chain activity and reduced ATP production [102,103]. Moreover, significantly decreased levels of enzymes in the mitochondrial tricarboxylic acid cycle, key to the respiratory chain, have also been observed in AD patients [104]. Impairment of bioenergetic functions in mitochondria leads to the mitochondria generating high levels of ROS and free radicals. As discussed above, the serial processes that predate the appearance of plaques and tangles are responsible for the extensive toxic damage to neuron cells. Therefore, the mitochondrial cascade hypothesis has gained favor as the mechanism for the essential pathogenesis of AD, wherein mitochondrial alterations trigger the cascade of pathologic features [105,106].

Previous studies have revealed that there might be an intriguing connection between the altered mitochondrial function and APP processing [107]. APP processing is reported to occur in lipid raft domains, the membrane regions with abundant cholesterol and sphingolipids [108], such as MAMs. Additionally, A β has proven to be formatted in the

MAMs [109]. Thus, it is reasonable to speculate that C99 the substrate for the MAM-localized γ -secretase might appear in the MAMs. Consistent with this conjecture, researchers have reported that the increased C99 content emerges not only in endosomes but also at MAMs in AD patients and animal models [110]. The increased C99 localized at the MAMs has been revealed to provoke alterations in mitochondrial lipid composition, membrane potential and permeability [111]. Furthermore, the activation of sphingolipid turnover and hydrolysis would subsequently augment the ceramide concentration, which is a special characteristic in AD individuals [112], particularly in their mitochondrial membranes [113]. The high levels of ceramide are thought to change the properties of the lipid raft domains at the MAMs [114]. Additionally, increased ceramide in mitochondrial membranes disturbs the proper assembly and activity of mitochondrial respiratory supercomplexes (Figure 2 (2)), which are essential for optimal respiratory chain function [115]. Importantly, these alterations of γ -secretase activity and increased C99 content at the MAMs have been observed not only in PS-mutant cells and FAD patients but also in SAD patients [116]. One conclusion from the above findings is that the bioenergetic defects in AD are significantly caused by an increased ceramide concentration in the mitochondria, subsequently hindering the assembly and activity of respiratory supercomplexes, and that this effect is initially stimulated by the unprocessed MAM-localized C99. If true, the critical role of C99 in mitochondrial dysfunction at the early stages of AD pathogenesis is not an instigating factor but a consequence of MAMs dysfunction. Previous studies have also suggested that deficient mitochondrial bioenergy is caused by increased C99 content, rather than elevated A β production since it can develop in the absence of A β , which differs from the observations that mitochondrial respiration is reduced after the incubation with unphysiologically high concentrations of A β [117]. It is conceivable that abnormal mitochondrial respiration is caused by an elevated ratio of C99:A β rather than an increased ratio of A β ₄₂: A β ₄₀. However, the further research is necessary to fully elucidating this speculation.

Previous studies have revealed that the mitochondrial dynamics in AD cells are changed significantly [27]. Mitochondrial dynamics are the collective processes of the relative physiological balance between fission and fusion. The major dynamin-related GTPases with opposing effects are involved in mediating this physiological balance [118]. In mammals, mitochondrial fission requires dynamin-like protein 1 (DLP1) and fission 1 (FIS1), while mitochondrial fusion is regulated by mitochondrial outer membrane protein MFN1/2 and intermembrane protein optic atrophy protein 1 (OPA1) [119]. The imbalance of mitochondrial fission and fusion ultimately leads to mitochondrial dysfunction via abnormal mitochondrial morphology and distribution [120], which has been reported in AD fibroblasts [121]. Immunoblot analysis of hippocampal tissues from AD patients exhibits significantly decreased expression of DLP1, OPA1, MFN1/2 and increased FIS1 [122], suggesting that the balance of mitochondrial fission and fusion is prone to fission in AD (Figure 2(4)) [123]. MFN1 and MFN2 localized to the OMM can form homo- or hetero-oligomeric complexes via the interactions of their coiled-coil domains to tether adjacent mitochondria together (Figure 2(3)) [124]. While though to be exclusively located in the OMM, MFN2 has also been revealed in the ER membrane [125]. Thus, in addition to its role in mitochondrial fusion, MFN2 may also have an important role in tethering the mitochondria and ER together, eventually forming MAMs [126]. These findings explain why augmented mitochondrial fission in AD is inclined to occur around the MAMs [127] and why the abundant MAMs increases in AD. Additionally, OPA1, MFN1, MFN2 and FIS1, the mitochondrial membrane proteins, are re-distributed to the soma in AD neurons [123]. It has been reported that mitochondria are uniformly distributed in the neuronal cytosol of unaffected individuals (Figure 2(3)) while they form a 'ring' around the neuron nucleus in AD patients (Figure 2(4)). Perinuclear localization of the majority of the ER and the increased MAMs in AD patients contribute to the mitochondrial accumulation around the perinuclear in AD. The perinuclear phenotype of mitochondria has also been reproduced in mouse models of AD [128,129]. Interestingly, the previous studies have demonstrated that the compatible ablation of both fusion and fission exhibits a wild-type mitochondrial morphology but also shows significantly massive mitochondrial DNA (mtDNA) loss, suggesting that the mitochondrial fusion and fission play essential roles in maintaining the mitochondrial genome [130]. Genetically, high levels of mtDNA deletions that can result in COX deficiency, a phenotype significantly present in AD patients' cells and tissues [131]. Future research will be essential to investigate if mtDNA deletions can be induced by MAM-mediated mitochondrial fusion and fission and by what mechanism, ultimately developing the pathogenesis of AD.

Other mechanisms mediated by MAMs in AD pathogenesis

Autophagy can effectively clear the damaged/dead cells and long-lived protein aggregates, in normal neurons [132]. Autophagic regulation is comprised of two complicated signaling transduction pathways including the mTOR-dependent and mTOR-independent mechanisms, both of which are involved in the AD pathology [133,134]. Researchers have hypothesized that impaired autophagy significantly reduces the clearance of A β and tau deposition

in the brain of AD patients and animal models [135]. In return, both enhanced A β deposit and NFTs can promote defective autophagy in AD [136]. Moreover, previous reports have demonstrated that ACAT1 blockage via the ACAT1 inhibitor K604 or *ACAT1* gene knockout can promote the autophagosome formation and lysosomal proteolysis in an mTOR signaling-independent manner, ultimately facilitating the degradation of A β 42 in AD neurons [137,138]. However, ACAT1 blockage has no effect on the total cell cholesterol content, indicating that ACAT1 blockage induces autophagy through a different mechanism [139]. Because MAMs are enriched in ACAT1 protein and cholesterol/sphingolipid, some researchers speculate that ACAT1 blockage might elevate the local cholesterol levels in the MAMs and that this alteration may mediate the enhanced autophagic function [140]. These findings suggest MAMs play an important role in the biogenesis of autophagosome.

Moreover, mitochondria and the ER are two the main intracellular locations for ROS generation and these ROS can exchange at the MAMs. As such, multiple oxidative regulators are located at the MAMs, the most common of which is p66Shc. The concentration of p66Shc, a cytosolic adaptor protein, increases at the MAMs, an observation consistent with mitochondrial ROS production in age-related diseases [141]. Previous studies have revealed that p66Shc activation renders central neuron system cells more vulnerable to A β toxicity via the promotion of mitochondrial ROS production, ultimately leading to the extensive neuronal death in AD [142]. Additionally, the RNA-dependent protein kinase (PKR)-like ER kinase (PERK) is a major ER stress sensor in the unfolded protein response, which is enriched in the MAMs and critical for maintaining their integrity. Furthermore, PERK has the ability to facilitate ROS exchanges between the ER and mitochondria. PERK deficiency can disturb the ER morphology and reduce ROS exchanges between the ER and mitochondria [143], which has been shown to attenuate neurodegeneration and memory deficits in AD mouse models [144]. Taken together, these findings imply that MAMs play a key role in ROS-based ER stress and the subsequent ROS-mediated mitochondrial apoptosis in AD. However, experiments are necessary for verifying the above findings.

Conclusion

In conclusion, we believe that the evidence supports the MAMs hypothesis as the fundamental for the biochemical and morphological phenotypes in AD as MAMs dysfunction provides an accurate explanation for early phenotypes discovered in both FAD and SAD, including aberrant calcium regulation, elevated lipid levels, mitochondrial dysfunction, autophagy and oxidative stress, all of which precede the appearance of plaques and tangles [145]. Moreover, alterations at the MAMs can be observed in not only neuronal cells but also non-neuronal tissues such as fibroblasts from AD patients [146], further supporting that MAMs play an important role in the pathogenesis of AD. The MAMs hypothesis emphasizes that plaques and tangles are not causes, but indeed, the final consequences of AD pathogenesis. Rather than repudiate the involvement of plaques and tangles in AD pathogenesis due to the fact that the amyloid cascade hypothesis could not explain various events seemingly irrelevant to plaques and tangles, MAMs hypothesis provides such explanations. In practice, perturbed MAMs function can also trigger the amyloid cascade, ultimately contributing to the downstream accumulation of plaques and tangles. Although MAMs regulate the pathogenesis of AD via various mechanisms, there are close interactions among these disparate mechanisms (Figure 4). Elevated intracellular Ca²⁺ mediated by MAMs can lead to mitochondrial dysfunction by increasing the mPTP opening in the mitochondria, while MAM-mediated mitochondrial dysfunction promotes the intracellular aberrant calcium influx and increased MAMs activity disturbs lipid homeostasis [147]. Additionally, mitochondrial dysfunction can increase the MAMs-mediated ROS generation, which subsequently contributes ER stress. ER stress can decrease the formation of autophagosomes, which significantly reduces the clearance of A β and tau deposition in AD. In addition to ER stress, disturbed cholesterol in MAMs via ACTA1 can also impair the autophagy. Ultimately, all of the serial cellular damage events mediated by aberrant MAMs function can directly or indirectly lead to A β deposition and NFTs formation, resulting in the neuronal dysfunction and apoptosis [148].

AD is recognized as the one of the major burden for patients, family and health-care systems in modern medicine. Although extensive efforts have been made into the AD therapeutic research for effective drugs, namely anti-A β therapies and anti-tau approaches, initial trials have produced discouraging results and the therapeutic studies are still at an impasse. Alternative targets must be sought. The MAMs hypothesis might provide just such a therapeutic target for the diagnosis and treatment of AD. For instance, the expression levels of ACAT1 can be used to measure the upregulated MAMs activity in AD patients. It may be possible to take advantage of these alterations to diagnose AD far earlier than current methodologies allow. Similarly, increased phospholipid and CE synthesis mediated by increased MAMs in relatively accessible cells could be used as markers for the diagnosis of AD. Furthermore, methods aimed at recovering normal MAMs function may be more effective therapeutics than trying to eliminate the accumulation of plaques and tangles, since they are secondary to the aberrant MAM function. The availability of reliable biomarkers




Figure 4. Schematic depiction of MAMs in AD

Altered MAMs function can directly affect the indicated pathways, including intracellular aberrant calcium, lipid homeostasis, mitochondrial dysfunction, oxidative stress and autophagy. Each of which can have one or more effects that ultimately lead to the pathologic changes in AD. Although the relative one-to-one connection between MAMs functions and AD pathologies has been outlined, there are close interactions among those various MAMs functions. The serial events mediated by aberrant MAMs function can ultimately result in neuronal dysfunction and apoptosis. see text for details. MAM, Mitochondria-Associated Membrane; AD, Alzheimer’s disease; mtPTP, mitochondrial permeability transition pore; A β , β -amyloid; ER, endoplasmic reticulum; ROS, reactive oxygen species; ACAT1, cholesterol acyltransferase 1.

that track MAMs functions and are associated with the clinical cognitive decline significantly enhances the likelihood of developing the disease-improving drugs.

However, there are still questions that urgently need answers. First, although findings have demonstrated that the functional changes in AD are primarily due to the increased ER-mitochondria communication and up-regulated MAM function, the biochemical upstream causes of ER-mitochondrial hyper-connectivity and perturbed MAM functions still remain a mystery. At time of writing, only a small fraction of the total molecules at the MAMs have been identified. Therefore, further clarification and identification of the unknown molecules at the MAMs will greatly facilitate comprehension of the underlying mechanisms involved in the ER-mitochondria communication and MAMs

functions. Conversely, the plethora of as yet unidentified targets reinforces the feasibility that targets for the maintenance and modulation of MAMs function will be identified and be viable as the novel potential drug targets for future AD therapy. Second, in addition to the contacts to the ER, the mitochondria also naturally interact with other organelles, which leads to a high risk of unnecessary organelle cross-contamination when isolating highly purified plasma associated membrane (PAM) and MAMs fractions. Given the difficulty in researching the MAMs' proteins and lipid compositions, it is essential to combine microscopy visualization techniques with high-throughput proteomics for further elucidation of the molecular compositions of the contacts between the mitochondria and other organelles. Doing so will ultimately enhance the knowledgebase of MAMs and PAM functions in AD. Third, it has been revealed that mitochondria can be linked to both smooth ER (10 nm width) and rough ER (25 nm width, due to the steric impediment of ribosomes) [130]. Intriguingly, although previous studies have showed that up to 80% of the mitochondria are associated with rough ER [149], comparisons of protein profiles between MAMs and smooth or rough ER membranes demonstrate that the proteins at the MAMs are more analogous to the smooth ER than rough ER [93]. Extensive researches related to the MAMs have regularly regarded the MAMs as identical with the diverse ER-mitochondria contact sites. However, there is no strong evidence that purified MAMs consist of all ER-mitochondria contact sites such as rough and smooth ER. Moreover, there is yet no relevant research so far to prove whether mitochondria-smooth ER, mitochondria-rough ER, or both play important roles in AD pathological changes. Therefore, although the MAM hypothesis provides new ways to think about the AD diagnosis and treatment, further studies must be developed to determine the most relevant mechanisms mediated by MAMs.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China [NSFC: 81971115].

Author Contribution

Yining Huang and Weiwei Yu were involved in devising the concept. Weiwei Yu contributed to drafting this manuscript. Yining Huang and Haiqiang Jin were involved in revising the manuscript and all authors approved the final version of the manuscript.

Abbreviations

A β , β -amyloid; ABAD, alcohol dehydrogenase; ACAT1, cholesterol acyltransferase 1; ACM, astrocyte-conditioned media; AD, Alzheimer's disease; AICD, APP intracellular domain; AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid; APOE4, apolipoprotein E; APP, amyloid precursor protein; ATP, adenosine triphosphate; BACE1, β -secretase; Ca²⁺, calcium ion; CE, cholesteryl ester; COX, cytochrome c oxidase; DLP1, dynamin-like protein 1; ER, endoplasmic reticulum; FAD, familial AD; FIS1, fission 1; IMM, inner mitochondrial matrix; IP3R, inositol triphosphate receptor; LTD, long-term depression; LTP, long-term potentiation; MAM, mitochondria-associated membrane; MCU, mitochondrial Ca²⁺ uniporter; MFN2, Mitofusin-2; mtPTP, mitochondrial permeability transition pore; NFT, neurofibrillary tangle; NMDA, N-methyl-D-aspartic acid; OMM, outer mitochondrial membrane; OPA1, optic atrophy protein 1; OR, odds ratio; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PEMT, PE-N-methyltransferase; PERK, RNA-dependent protein kinase (PKR)-like ER kinase; PS, phosphatidylserine; PSD, PS decarboxylase; PSEN1, presenilin 1; PSEN2, presenilin 2; ROS, reactive oxygen species; RyR, ryanodine receptor; SAD, sporadic AD; SERCA, sarco-ER calcium-ATPase; Sig-1R, sigma-1 receptor; TRP, transient receptor potential; VDAC1, voltage-dependent anion channel 1; VGCC, voltage-gate Ca²⁺ channel.

References

- Lane, C.A., Hardy, J. and Schott, J.M. (2018) Alzheimer's disease. *Eur. J. Neurol.* **25**, 59–70, <https://doi.org/10.1111/ene.13439>
- Baumgart, M., Snyder, H.M., Carrillo, M.C., Fazio, S., Kim, H. and Johns, H. (2015) Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. *Alzheimers Dement* **11**, 718–726, <https://doi.org/10.1016/j.jalz.2015.05.016>
- Mattson, M.P. (2010) ER calcium and Alzheimer's disease: in a state of flux. *Sci. Signal* **3**, pe10, <https://doi.org/10.1126/scisignal.3114pe10>
- (2020) 2020 Alzheimer's disease facts and figures. *Alzheimer's & Dementia: J. Alzheimer's Assoc.* **16**, 391–460, <https://doi.org/10.1002/alz.12068>
- Liang, J., Kulasiri, D. and Samarasinghe, S. (2015) Ca²⁺ dysregulation in the endoplasmic reticulum related to Alzheimer's disease: A review on experimental progress and computational modeling. *Biosystems* **134**, 1–15, <https://doi.org/10.1016/j.biosystems.2015.05.003>
- Hardy, J. (2006) A hundred years of Alzheimer's disease research. *Neuron* **52**, 3–13, <https://doi.org/10.1016/j.neuron.2006.09.016>
- Bateman, R.J., Aisen, P.S., De Strooper, B., Fox, N.C., Lemere, C.A., Ringman, J.M. et al. (2011) Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. *Alzheimers Res. Ther.* **3**, 1, <https://doi.org/10.1186/alzrt59>
- Alzheimer, A., Stelzmann, R.A., Schnitzlein, H.N. and Murtagh, F.R. (1995) An English translation of Alzheimer's 1907 paper, "Über eine eigenartige Erkrankung der Hirnrinde". *Clin. Anat.* **8**, 429–431

- 9 Serrano-Pozo, A., Frosch, M.P., Masliah, E. and Hyman, B.T. (2011) Neuropathological alterations in Alzheimer disease. *Cold Spring Harb. Perspect. Med.* **1**, a006189, <https://doi.org/10.1101/cshperspect.a006189>
- 10 Itagaki, S., McGeer, P.L., Akiyama, H., Zhu, S. and Selkoe, D. (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. *J. Neuroimmunol.* **24**, 173–182, [https://doi.org/10.1016/0165-5728\(89\)90115-X](https://doi.org/10.1016/0165-5728(89)90115-X)
- 11 Masliah, E., Mallory, M., Hansen, L., Alford, M., Albricht, T., Terry, R. et al. (1991) Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease. *Acta Neuropathol.* **83**, 12–20, <https://doi.org/10.1007/BF00294425>
- 12 Hardy, J.A. and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. *Science* **256**, 184–185, <https://doi.org/10.1126/science.1566067>
- 13 Karran, E., Mercken, M. and De Strooper, B. (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. *Nat. Rev. Drug Discov.* **10**, 698–712, <https://doi.org/10.1038/nrd3505>
- 14 Boix, C.P., Lopez-Font, I., Cuchillo-Ibañez, I. and Sáez-Valero, J. (2020) Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer's disease. *Alzheimers Res Ther* **12**, 96, <https://doi.org/10.1186/s13195-020-00664-9>
- 15 Leissring, M.A., Murphy, M.P., Mead, T.R., Akbari, Y., Sugarman, M.C., Jannatipour, M. et al. (2002) A physiologic signaling role for the gamma-secretase-derived intracellular fragment of APP. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 4697–4702, <https://doi.org/10.1073/pnas.072033799>
- 16 Bezprozvanny, I. and Mattson, M.P. (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. *Trends Neurosci.* **31**, 454–463, <https://doi.org/10.1016/j.tins.2008.06.005>
- 17 Welander, H., Frånberg, J., Graff, C., Sundström, E., Winblad, B. and Tjernberg, L.O. (2009) Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. *J. Neurochem.* **110**, 697–706, <https://doi.org/10.1111/j.1471-4159.2009.06170.x>
- 18 Gravina, S.A., Ho, L., Eckman, C.B., Long, K.E., Otvos, Jr, L., Younkin, L.H. et al. (1995) Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). *J. Biol. Chem.* **270**, 7013–7016, <https://doi.org/10.1074/jbc.270.13.7013>
- 19 De Strooper, B. (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. *Neuron* **38**, 9–12, [https://doi.org/10.1016/S0896-6273\(03\)00205-8](https://doi.org/10.1016/S0896-6273(03)00205-8)
- 20 Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N. et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat. Med.* **2**, 864–870, <https://doi.org/10.1038/nm0896-864>
- 21 Mattson, M.P. (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. *Physiol. Rev.* **77**, 1081–1132, <https://doi.org/10.1152/physrev.1997.77.4.1081>
- 22 Wang, Y. and Mandelkow, E. (2016) Tau in physiology and pathology. *Nat. Rev. Neurosci.* **17**, 5–21, <https://doi.org/10.1038/nrn.2015.1>
- 23 Iqbal, K., Liu, F., Gong, C.X. and Grundke-Iqbal, I. (2010) Tau in Alzheimer disease and related tauopathies. *Curr. Alzheimer Res.* **7**, 656–664, <https://doi.org/10.2174/156720510793611592>
- 24 Khan, S.S. and Bloom, G.S. (2016) Tau: The Center of a Signaling Nexus in Alzheimer's Disease. *Front. Neurosci.* **10**, 31, <https://doi.org/10.3389/fnins.2016.00031>
- 25 Stefani, M. and Liguri, G. (2009) Cholesterol in Alzheimer's disease: unresolved questions. *Curr. Alzheimer Res.* **6**, 15–29, <https://doi.org/10.2174/156720509787313899>
- 26 Pettegrew, J.W., Panchalingam, K., Hamilton, R.L. and McClure, R.J. (2001) Brain membrane phospholipid alterations in Alzheimer's disease. *Neurochem. Res.* **26**, 771–782, <https://doi.org/10.1023/A:1011603916962>
- 27 Wang, X., Su, B., Zheng, L., Perry, G., Smith, M.A. and Zhu, X. (2009) The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. *J. Neurochem.* **109**, 153–159, <https://doi.org/10.1111/j.1471-4159.2009.05867.x>
- 28 Gabaldón, T. and Pittis, A.A. (2015) Origin and evolution of metabolic sub-cellular compartmentalization in eukaryotes. *Biochimie* **119**, 262–268, <https://doi.org/10.1016/j.biochi.2015.03.021>
- 29 Copeland, D.E. and Dalton, A.J. (1959) An association between mitochondria and the endoplasmic reticulum in cells of the pseudobranch gland of a teleost. *J. Biophys. Biochem. Cytol.* **5**, 393–396, <https://doi.org/10.1083/jcb.5.3.393>
- 30 Bereiter-Hahn, J. (1990) Behavior of mitochondria in the living cell. *Int. Rev. Cytol.* **122**, 1–63, [https://doi.org/10.1016/S0074-7696\(08\)61205-X](https://doi.org/10.1016/S0074-7696(08)61205-X)
- 31 Yang, M., Li, C. and Sun, L. (2020) Mitochondria-Associated Membranes (MAMs): A Novel Therapeutic Target for Treating Metabolic Syndrome. *Curr. Med. Chem.*
- 32 Friedman, J.R., Lackner, L.L., West, M., DiBenedetto, J.R., Nunnari, J. and Voeltz, G.K. (2011) ER tubules mark sites of mitochondrial division. *Science* **334**, 358–362, <https://doi.org/10.1126/science.1207385>
- 33 Rowland, A.A. and Voeltz, G.K. (2012) Endoplasmic reticulum-mitochondria contacts: function of the junction. *Nat. Rev. Mol. Cell Biol.* **13**, 607–625, <https://doi.org/10.1038/nrm3440>
- 34 Zhang, A., Williamson, C.D., Wong, D.S., Bullough, M.D., Brown, K.J., Hathout, Y. et al. (2011) Quantitative proteomic analyses of human cytomegalovirus-induced restructuring of endoplasmic reticulum-mitochondrial contacts at late times of infection. *Mol. Cell. Proteomics* **10**, M111.009936, <https://doi.org/10.1074/mcp.M111.009936>
- 35 Poston, C.N., Krishnan, S.C. and Bazemore-Walker, C.R. (2013) In-depth proteomic analysis of mammalian mitochondria-associated membranes (MAM). *J. Proteomics* **79**, 219–230, <https://doi.org/10.1016/j.jprot.2012.12.018>
- 36 Rizzuto, R., Pinton, P., Carrington, W., Fay, F.S., Fogarty, K.E., Lifshitz, L.M. et al. (1998) Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca²⁺ responses. *Science* **280**, 1763–1766, <https://doi.org/10.1126/science.280.5370.1763>
- 37 Achleitner, G., Gaigg, B., Krasser, A., Kainersdorfer, E., Kohlwein, S.D., Perktold, A. et al. (1999) Association between the endoplasmic reticulum and mitochondria of yeast facilitates interorganelle transport of phospholipids through membrane contact. *Eur. J. Biochem.* **264**, 545–553, <https://doi.org/10.1046/j.1432-1327.1999.00658.x>

- 38 Paillusson, S., Stoica, R., Gomez-Suaga, P., Lau, D.H.W., Mueller, S., Miller, T. et al. (2016) There's Something Wrong with my MAM; the ER-Mitochondria Axis and Neurodegenerative Diseases. *Trends Neurosci.* **39**, 146–157, <https://doi.org/10.1016/j.tins.2016.01.008>
- 39 Csordás, G., Renken, C., Várnai, P., Walter, L., Weaver, D., Buttler, K.F. et al. (2006) Structural and functional features and significance of the physical linkage between ER and mitochondria. *J. Cell Biol.* **174**, 915–921, <https://doi.org/10.1083/jcb.200604016>
- 40 Soltys, B.J. and Gupta, R.S. (1992) Interrelationships of endoplasmic reticulum, mitochondria, intermediate filaments, and microtubules—a quadruple fluorescence labeling study. *Biochem. Cell. Biol.* **70**, 1174–1186, <https://doi.org/10.1139/o92-163>
- 41 Krols, M., van Isterdael, G., Asselbergh, B., Kremer, A., Lippens, S., Timmerman, V. et al. (2016) Mitochondria-associated membranes as hubs for neurodegeneration. *Acta Neuropathol.* **131**, 505–523, <https://doi.org/10.1007/s00401-015-1528-7>
- 42 Area-Gomez, E., de Groof, A.J., Boldogh, I., Bird, T.D., Gibson, G.E., Koehler, C.M. et al. (2009) Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. *Am. J. Pathol.* **175**, 1810–1816, <https://doi.org/10.2353/ajpath.2009.090219>
- 43 Stoica, R., De Vos, K.J., Paillusson, S., Mueller, S., Sancho, R.M., Lau, K.F. et al. (2014) ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. *Nat. Commun.* **5**, 3996, <https://doi.org/10.1038/ncomms4996>
- 44 Ottolini, D., Cali, T., Negro, A. and Brini, M. (2013) The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. *Hum. Mol. Genet.* **22**, 2152–2168, <https://doi.org/10.1093/hmg/ddt068>
- 45 Watanabe, S., Ilieva, H., Tamada, H., Nomura, H., Komine, O., Endo, F. et al. (2016) Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR1- and SOD1-linked ALS. *EMBO Mol. Med.* **8**, 1421–1437, <https://doi.org/10.15252/emmm.201606403>
- 46 Stoica, R., Paillusson, S., Gomez-Suaga, P., Mitchell, J.C., Lau, D.H., Gray, E.H. et al. (2016) ALS/FTD-associated FUS activates GSK-3 β to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations. *EMBO Rep.* **17**, 1326–1342, <https://doi.org/10.15252/embr.201541726>
- 47 Area-Gomez, E., Del Carmen Lara Castillo, M., Tambini, M.D., Guardia-Laguarta, C., de Groof, A.J., Madra, M. et al. (2012) Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. *EMBO J.* **31**, 4106–4123, <https://doi.org/10.1038/emboj.2012.202>
- 48 Hedskog, L., Pinho, C.M., Filadi, R., Ronnback, A., Hertwig, L., Wiehager, B. et al. (2013) Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 7916–7921, <https://doi.org/10.1073/pnas.1300677110>
- 49 Wertkin, A.M., Turner, R.S., Pleasure, S.J., Golde, T.E., Younkin, S.G., Trojanowski, J.Q. et al. (1993) Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides. *Proc. Natl. Acad. Sci. U. S. A.* **90**, 9513–9517, <https://doi.org/10.1073/pnas.90.20.9513>
- 50 Fernández-Vizarra, P., Fernández, A.P., Castro-Blanco, S., Serrano, J., Bentura, M.L., Martínez-Murillo, R. et al. (2004) Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. *Histol. Histopathol.* **19**, 823–844
- 51 Schmitz, C., Rutten, B.P., Pielon, A., Schäfer, S., Wirths, O., Tremp, G. et al. (2004) Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. *Am. J. Pathol.* **164**, 1495–1502, [https://doi.org/10.1016/S0002-9440\(10\)63235-X](https://doi.org/10.1016/S0002-9440(10)63235-X)
- 52 Masters, C.L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R.N. and Beyreuther, K. (1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. *EMBO J.* **4**, 2757–2763, <https://doi.org/10.1002/j.1460-2075.1985.tb04000.x>
- 53 Blanchard, V., Moussaoui, S., Czech, C., Touchet, N., Bonici, B., Planche, M. et al. (2003) Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. *Exp. Neurol.* **184**, 247–263, [https://doi.org/10.1016/S0014-4886\(03\)00252-8](https://doi.org/10.1016/S0014-4886(03)00252-8)
- 54 Takahashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi, H. et al. (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. *Am. J. Pathol.* **161**, 1869–1879, [https://doi.org/10.1016/S0002-9440\(10\)64463-X](https://doi.org/10.1016/S0002-9440(10)64463-X)
- 55 Wang, X., Su, B., Perry, G., Smith, M.A. and Zhu, X. (2007) Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. *Free Radic. Biol. Med.* **43**, 1569–1573, <https://doi.org/10.1016/j.freeradbiomed.2007.09.007>
- 56 Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J.W. et al. (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. *FASEB J.* **19**, 2040–2041, <https://doi.org/10.1096/fj.05-3735fje>
- 57 Lustbader, J.W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K., Wang, N. et al. (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. *Science* **304**, 448–452, <https://doi.org/10.1126/science.1091230>
- 58 Devi, L., Prabhu, B.M., Galati, D.F., Avadhani, N.G. and Anandatheerthavarada, H.K. (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. *J. Neurosci.* **26**, 9057–9068, <https://doi.org/10.1523/JNEUROSCI.1469-06.2006>
- 59 Hansson Petersen, C.A., Alikhani, N., Behbahani, H., Wiehager, B., Pavlov, P.F., Alafuzoff, I. et al. (2008) The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 13145–13150, <https://doi.org/10.1073/pnas.0806192105>
- 60 Schreiner, B., Hedskog, L., Wiehager, B. and Ankarcrona, M. (2015) Amyloid-beta peptides are generated in mitochondria-associated endoplasmic reticulum membranes. *J. Alzheimers Dis.* **43**, 369–374, <https://doi.org/10.3233/JAD-132543>
- 61 Cottrell, D.A., Borthwick, G.M., Johnson, M.A., Ince, P.G. and Turnbull, D.M. (2002) The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer's disease. *Neuropathol. Appl. Neurobiol.* **28**, 390–396, <https://doi.org/10.1046/j.1365-2990.2002.00414.x>
- 62 Berridge, M.J., Bootman, M.D. and Lipp, P. (1998) Calcium—a life and death signal. *Nature* **395**, 645–648, <https://doi.org/10.1038/27094>
- 63 Piegari, E., Villarruel, C. and Ponce Dawson, S. (2019) Changes in Ca(2+) Removal Can Mask the Effects of Geometry During IP3R Mediated Ca(2+) Signals. *Front. Physiol.* **10**, 964, <https://doi.org/10.3389/fphys.2019.00964>
- 64 Lanner, J.T., Georgiou, D.K., Joshi, A.D. and Hamilton, S.L. (2010) Ryanodine receptors: structure, expression, molecular details, and function in calcium release. *Cold Spring Harb. Perspect. Biol.* **2**, a003996, <https://doi.org/10.1101/cshperspect.a003996>
- 65 Neymotin, S.A., McDougal, R.A., Bulanova, A.S., Zeki, M., Lakatos, P., Terman, D. et al. (2016) Calcium regulation of HCN channels supports persistent activity in a multiscale model of neocortex. *Neuroscience* **316**, 344–366, <https://doi.org/10.1016/j.neuroscience.2015.12.043>

- 66 Tarasov, A.I., Griffiths, E.J. and Rutter, G.A. (2012) Regulation of ATP production by mitochondrial Ca²⁺. *Cell Calcium* **52**, 28–35, <https://doi.org/10.1016/j.ceca.2012.03.003>
- 67 Popugaeva, E. and Bezprozvanny, I. (2013) Role of endoplasmic reticulum Ca²⁺ signaling in the pathogenesis of Alzheimer disease. *Front. Mol. Neurosci.* **6**, 29, <https://doi.org/10.3389/fnmol.2013.00029>
- 68 Malli, R. and Graier, W.F. (2017) The Role of Mitochondria in the Activation/Maintenance of SOCE: The Contribution of Mitochondrial Ca²⁺ Uptake, Mitochondrial Motility, and Location to Store-Operated Ca²⁺ Entry. *Adv. Exp. Med. Biol.* **993**, 297–319, https://doi.org/10.1007/978-3-319-57732-6_16
- 69 Filadi, R., Theurey, P. and Pizzo, P. (2017) The endoplasmic reticulum-mitochondria coupling in health and disease: Molecules, functions and significance. *Cell Calcium* **62**, 1–15, <https://doi.org/10.1016/j.ceca.2017.01.003>
- 70 Danese, A., Patergnani, S., Bonora, M., Wieckowski, M.R., Previati, M., Giorgi, C. et al. (2017) Calcium regulates cell death in cancer: Roles of the mitochondria and mitochondria-associated membranes (MAMs). *Biochim. Biophys. Acta Bioenerg.* **1858**, 615–627, <https://doi.org/10.1016/j.bbabi.2017.01.003>
- 71 Khachaturian, Z.S. (1994) Calcium hypothesis of Alzheimer's disease and brain aging. *Ann. N. Y. Acad. Sci.* **747**, 1–11, <https://doi.org/10.1111/j.1749-6632.1994.tb44398.x>
- 72 (2017) Calcium Hypothesis of Alzheimer's disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis. *Alzheimers Dement* **13**, 178.e117–182.e117
- 73 Poon, H.F., Shepherd, H.M., Reed, T.T., Calabrese, V., Stella, A.M., Pennisi, G. et al. (2006) Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: Mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. *Neurobiol. Aging* **27**, 1020–1034, <https://doi.org/10.1016/j.neurobiolaging.2005.05.014>
- 74 Emilsson, L., Sætre, P. and Jazin, E. (2006) Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling. *Neurobiol. Dis.* **21**, 618–625, <https://doi.org/10.1016/j.nbd.2005.09.004>
- 75 Hayashi, T., Rizzuto, R., Hajnoczky, G. and Su, T.P. (2009) MAM: more than just a housekeeper. *Trends Cell Biol.* **19**, 81–88, <https://doi.org/10.1016/j.tcb.2008.12.002>
- 76 García-Pérez, C., Hajnóczky, G. and Csordás, G. (2008) Physical coupling supports the local Ca²⁺ transfer between sarcoplasmic reticulum subdomains and the mitochondria in heart muscle. *J. Biol. Chem.* **283**, 32771–32780, <https://doi.org/10.1074/jbc.M803385200>
- 77 de Meis, L., Ketzler, L.A., da Costa, R.M., de Andrade, I.R. and Benchimol, M. (2010) Fusion of the endoplasmic reticulum and mitochondrial outer membrane in rats brown adipose tissue: activation of thermogenesis by Ca²⁺. *PLoS ONE* **5**, e9439, <https://doi.org/10.1371/journal.pone.0009439>
- 78 Hayashi, T. and Fujimoto, M. (2010) Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction. *Mol. Pharmacol.* **77**, 517–528, <https://doi.org/10.1124/mol.109.062539>
- 79 D'Eletto, M., Rossin, F., Occhigrossi, L., Farrace, M.G., Faccenda, D., Desai, R. et al. (2018) Transglutaminase Type 2 Regulates ER-Mitochondria Contact Sites by Interacting with GRP75. *Cell Rep.* **25**, 3573.e3574–3581.e3574
- 80 Zampese, E., Fasolato, C., Kipanyula, M.J., Bortolozzi, M., Pozzan, T. and Pizzo, P. (2011) Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca²⁺ cross-talk. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 2777–2782, <https://doi.org/10.1073/pnas.1100735108>
- 81 Jayadev, S., Leverenz, J.B., Steinbart, E., Stahl, J., Klunk, W., Yu, C.E. et al. (2010) Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. *Brain* **133**, 1143–1154, <https://doi.org/10.1093/brain/awq033>
- 82 Unni, V.K., Zakharenko, S.S., Zablou, L., DeCostanzo, A.J. and Siegelbaum, S.A. (2004) Calcium release from presynaptic ryanodine-sensitive stores is required for long-term depression at hippocampal CA3-CA3 pyramidal neuron synapses. *J. Neurosci.* **24**, 9612–9622, <https://doi.org/10.1523/JNEUROSCI.5583-03.2004>
- 83 Cuestas Torres, D.M. and Cardenas, F.P. (2020) Synaptic plasticity in Alzheimer's disease and healthy aging. *Rev. Neurosci.* **31**, 245–268, <https://doi.org/10.1515/revneuro-2019-0058>
- 84 Sanz-Blasco, S., Valero, R.A., Rodriguez-Crespo, I., Villalobos, C. and Nunez, L. (2008) Mitochondrial Ca²⁺ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. *PLoS ONE* **3**, e2718, <https://doi.org/10.1371/journal.pone.0002718>
- 85 Giacomello, M., Drago, I., Pizzo, P. and Pozzan, T. (2007) Mitochondrial Ca²⁺ as a key regulator of cell life and death. *Cell Death Differ.* **14**, 1267–1274, <https://doi.org/10.1038/sj.cdd.4402147>
- 86 Nixon, R.A., Saito, K.I., Grynspan, F., Griffin, W.R., Katayama, S., Honda, T. et al. (1994) Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. *Ann. N. Y. Acad. Sci.* **747**, 77–91, <https://doi.org/10.1111/j.1749-6632.1994.tb44402.x>
- 87 Mattson, M.P. (1990) Antigenic changes similar to those seen in neurofibrillary tangles are elicited by glutamate and Ca²⁺ influx in cultured hippocampal neurons. *Neuron* **4**, 105–117, [https://doi.org/10.1016/0896-6273\(90\)90447-N](https://doi.org/10.1016/0896-6273(90)90447-N)
- 88 Pierrot, N., Santos, S.F., Feyt, C., Morel, M., Brion, J.P. and Octave, J.N. (2006) Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation. *J. Biol. Chem.* **281**, 39907–39914, <https://doi.org/10.1074/jbc.M606015200>
- 89 Guo, Q., Sopher, B.L., Furukawa, K., Pham, D.G., Robinson, N., Martin, G.M. et al. (1997) Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. *J. Neurosci.* **17**, 4212–4222, <https://doi.org/10.1523/JNEUROSCI.17-11-04212.1997>
- 90 Jo, D.G., Arumugam, T.V., Woo, H.N., Park, J.S., Tang, S.C., Mughal, M. et al. (2010) Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease. *Neurobiol. Aging* **31**, 917–925, <https://doi.org/10.1016/j.neurobiolaging.2008.07.003>
- 91 Stutzmann, G.E., Smith, I., Caccamo, A., Oddo, S., Laferla, F.M. and Parker, I. (2006) Enhanced ryanodine receptor recruitment contributes to Ca²⁺ disruptions in young, adult, and aged Alzheimer's disease mice. *J. Neurosci.* **26**, 5180–5189, <https://doi.org/10.1523/JNEUROSCI.0739-06.2006>
- 92 Flis, V.V. and Daum, G. (2013) Lipid transport between the endoplasmic reticulum and mitochondria. *Cold Spring Harb. Perspect. Biol.* **5**, <https://doi.org/10.1101/cshperspect.a013235>

- 93 Vance, J.E. (1990) Phospholipid synthesis in a membrane fraction associated with mitochondria. *J. Biol. Chem.* **265**, 7248–7256
- 94 Vance, J.E. (2014) MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. *Biochim. Biophys. Acta* **1841**, 595–609, <https://doi.org/10.1016/j.bbailp.2013.11.014>
- 95 Voelker, D.R. (2005) Bridging gaps in phospholipid transport. *Trends Biochem. Sci.* **30**, 396–404, <https://doi.org/10.1016/j.tibs.2005.05.008>
- 96 Prasad, M., Kaur, J., Pawlak, K.J., Bose, M., Whittal, R.M. and Bose, H.S. (2015) Mitochondria-associated endoplasmic reticulum membrane (MAM) regulates steroidogenic activity via steroidogenic acute regulatory protein (StAR)-voltage-dependent anion channel 2 (VDAC2) interaction. *J. Biol. Chem.* **290**, 2604–2616, <https://doi.org/10.1074/jbc.M114.605808>
- 97 Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L.A., Berezovska, O., Hyman, B.T. et al. (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. *Nat. Cell Biol.* **3**, 905–912, <https://doi.org/10.1038/ncb1001-905>
- 98 Puglielli, L., Ellis, B.C., Ingano, L.A. and Kovacs, D.M. (2004) Role of acyl-coenzyme a: cholesterol acyltransferase activity in the processing of the amyloid precursor protein. *J. Mol. Neurosci.* **24**, 93–96, <https://doi.org/10.1385/JMN:24:1:093>
- 99 Tambini, M.D., Pera, M., Kanter, E., Yang, H., Guardia-Laguarta, C., Holtzman, D. et al. (2016) ApoE4 upregulates the activity of mitochondria-associated ER membranes. *EMBO Rep.* **17**, 27–36, <https://doi.org/10.15252/embr.201540614>
- 100 de Brito, O.M. and Scorrano, L. (2008) Mitofusin 2 tethers endoplasmic reticulum to mitochondria. *Nature* **456**, 605–610, <https://doi.org/10.1038/nature07534>
- 101 Filadi, R., Greotti, E., Turacchio, G., Luini, A., Pozzan, T. and Pizzo, P. (2015) Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria coupling. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E2174–E2181, <https://doi.org/10.1073/pnas.1504880112>
- 102 Atamna, H. and Frey, 2nd, W.H. (2007) Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. *Mitochondrion* **7**, 297–310, <https://doi.org/10.1016/j.mito.2007.06.001>
- 103 Bosetti, F., Brizzi, F., Barogi, S., Mancuso, M., Siciliano, G., Tendi, E.A. et al. (2002) Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. *Neurobiol. Aging* **23**, 371–376, [https://doi.org/10.1016/S0197-4580\(01\)00314-1](https://doi.org/10.1016/S0197-4580(01)00314-1)
- 104 Gibson, G.E., Chen, H.L., Xu, H., Qiu, L., Xu, Z., Denton, T.T. et al. (2012) Deficits in the mitochondrial enzyme α -ketoglutarate dehydrogenase lead to Alzheimer's disease-like calcium dysregulation. *Neurobiol. Aging* **33**, 1121.e1113–1124.e1113, <https://doi.org/10.1016/j.neurobiolaging.2011.11.003>
- 105 Moreira, P.I., Carvalho, C., Zhu, X., Smith, M.A. and Perry, G. (2010) Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. *Biochim. Biophys. Acta* **1802**, 2–10, <https://doi.org/10.1016/j.bbadis.2009.10.006>
- 106 Swerdlow, R.H., Burns, J.M. and Khan, S.M. (2014) The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. *Biochim. Biophys. Acta* **1842**, 1219–1231, <https://doi.org/10.1016/j.bbadis.2013.09.010>
- 107 Lopez Sanchez, M.I.G., Waugh, H.S., Tsatsanis, A., Wong, B.X., Crowston, J.G., Duce, J.A. et al. (2017) Amyloid precursor protein drives down-regulation of mitochondrial oxidative phosphorylation independent of amyloid beta. *Sci. Rep.* **7**, 9835, <https://doi.org/10.1038/s41598-017-10233-0>
- 108 Cordy, J.M., Hooper, N.M. and Turner, A.J. (2006) The involvement of lipid rafts in Alzheimer's disease. *Mol. Membr. Biol.* **23**, 111–122, <https://doi.org/10.1080/09687860500496417>
- 109 Schreiner, B., Hedskog, L., Wiehager, B. and Ankarcrona, M. (2015) Amyloid- β peptides are generated in mitochondria-associated endoplasmic reticulum membranes. *J. Alzheimers Dis.* **43**, 369–374, <https://doi.org/10.3233/JAD-132543>
- 110 Pera, M., Larrea, D., Guardia-Laguarta, C., Montesinos, J., Velasco, K.R., Agrawal, R.R. et al. (2017) Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. *EMBO J.* **36**, 3356–3371, <https://doi.org/10.15252/embj.201796797>
- 111 Kogot-Levin, A. and Saada, A. (2014) Ceramide and the mitochondrial respiratory chain. *Biochimie* **100**, 88–94, <https://doi.org/10.1016/j.biochi.2013.07.027>
- 112 He, X., Huang, Y., Li, B., Gong, C.X. and Schuchman, E.H. (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. *Neurobiol. Aging* **31**, 398–408, <https://doi.org/10.1016/j.neurobiolaging.2008.05.010>
- 113 Kennedy, M.A., Moffat, T.C., Gable, K., Ganesan, S., Niewola-Staszewska, K., Johnston, A. et al. (2016) A Signaling Lipid Associated with Alzheimer's Disease Promotes Mitochondrial Dysfunction. *Sci. Rep.* **6**, 19332, <https://doi.org/10.1038/srep19332>
- 114 Dinkla, S., Wessels, K., Verdurmen, W.P., Tomelleri, C., Cluitmans, J.C., Fransen, J. et al. (2012) Functional consequences of sphingomyelinase-induced changes in erythrocyte membrane structure. *Cell Death. Dis.* **3**, e410, <https://doi.org/10.1038/cddis.2012.143>
- 115 Acin-Perez, R. and Enriquez, J.A. (2014) The function of the respiratory supercomplexes: the plasticity model. *Biochim. Biophys. Acta* **1837**, 444–450, <https://doi.org/10.1016/j.bbabi.2013.12.009>
- 116 Pera, M., Alcolea, D., Sánchez-Valle, R., Guardia-Laguarta, C., Colom-Cadena, M., Badiola, N. et al. (2013) Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. *Acta Neuropathol.* **125**, 201–213, <https://doi.org/10.1007/s00401-012-1062-9>
- 117 Casley, C.S., Canevari, L., Land, J.M., Clark, J.B. and Sharpe, M.A. (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. *J. Neurochem.* **80**, 91–100, <https://doi.org/10.1046/j.0022-3042.2001.00681.x>
- 118 McBride, H.M., Neuspiel, M. and Wasiak, S. (2006) Mitochondria: more than just a powerhouse. *Curr. Biol.* **16**, R551–R560, <https://doi.org/10.1016/j.cub.2006.06.054>
- 119 Okamoto, K. and Shaw, J.M. (2005) Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes. *Annu. Rev. Genet.* **39**, 503–536, <https://doi.org/10.1146/annurev.genet.38.072902.093019>
- 120 Chen, H., Chomyn, A. and Chan, D.C. (2005) Disruption of fusion results in mitochondrial heterogeneity and dysfunction. *J. Biol. Chem.* **280**, 26185–26192, <https://doi.org/10.1074/jbc.M503062200>

- 121 Wang, X., Su, B., Fujioka, H. and Zhu, X. (2008) Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. *Am. J. Pathol.* **173**, 470–482, <https://doi.org/10.2353/ajpath.2008.071208>
- 122 Yang, P., Sheng, D., Guo, Q., Wang, P., Xu, S., Qian, K. et al. (2020) Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease. *Biomaterials* **238**, 119844, <https://doi.org/10.1016/j.biomaterials.2020.119844>
- 123 Wang, X., Su, B., Siedlak, S.L., Moreira, P.I., Fujioka, H., Wang, Y. et al. (2008) Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 19318–19323, <https://doi.org/10.1073/pnas.0804871105>
- 124 Ishihara, N., Eura, Y. and Mihara, K. (2004) Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. *J. Cell Sci.* **117**, 6535–6546, <https://doi.org/10.1242/jcs.01565>
- 125 Basso, V., Marchesan, E., Peggion, C., Chakraborty, J., von Stockum, S., Giacomello, M. et al. (2018) Regulation of ER-mitochondria contacts by Parkin via Mfn2. *Pharmacol. Res.* **138**, 43–56, <https://doi.org/10.1016/j.phrs.2018.09.006>
- 126 Ainbinder, A., Boncompagni, S., Protasi, F. and Dirksen, R.T. (2015) Role of Mitofusin-2 in mitochondrial localization and calcium uptake in skeletal muscle. *Cell Calcium* **57**, 14–24, <https://doi.org/10.1016/j.ceca.2014.11.002>
- 127 de Brito, O.M. and Scorrano, L. (2010) An intimate liaison: spatial organization of the endoplasmic reticulum-mitochondria relationship. *EMBO J.* **29**, 2715–2723, <https://doi.org/10.1038/emboj.2010.177>
- 128 Manczak, M., Calkins, M.J. and Reddy, P.H. (2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. *Hum. Mol. Genet.* **20**, 2495–2509, <https://doi.org/10.1093/hmg/ddr139>
- 129 Manczak, M., Kandimalla, R., Yin, X. and Reddy, P.H. (2018) Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer's disease. *Hum. Mol. Genet.* **27**, 1332–1342, <https://doi.org/10.1093/hmg/ddy042>
- 130 Giorgi, C., De Stefani, D., Bononi, A., Rizzuto, R. and Pinton, P. (2009) Structural and functional link between the mitochondrial network and the endoplasmic reticulum. *Int. J. Biochem. Cell Biol.* **41**, 1817–1827, <https://doi.org/10.1016/j.biocel.2009.04.010>
- 131 Krishnan, K.J., Ratnaik, T.E., De Gruyter, H.L., Jaros, E. and Turnbull, D.M. (2012) Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease. *Neurobiol. Aging* **33**, 2210–2214, <https://doi.org/10.1016/j.neurobiolaging.2011.08.009>
- 132 Wu, M.Y., Song, J.X., Wang, S.F., Cai, C.Z., Li, M. and Lu, J.H. (2018) Selective autophagy: The new player in the fight against neurodegenerative diseases? *Brain Res. Bull.* **137**, 79–90, <https://doi.org/10.1016/j.brainresbull.2017.11.009>
- 133 Li, X., Song, J. and Dong, R. (2019) Cubeben induces autophagy via PI3K-AKT-mTOR pathway to protect primary neurons against amyloid beta in Alzheimer's disease. *Cytotechnology* **71**, 679–686, <https://doi.org/10.1007/s10616-019-00313-6>
- 134 Huang, L., Lin, M., Zhong, X., Yang, H. and Deng, M. (2019) Galangin decreases p-tau, A β 42 and β -secretase levels, and suppresses autophagy in okadaic acid-induced PC12 cells via an Akt/GSK3 β /mTOR signaling-dependent mechanism. *Mol. Med. Rep.* **19**, 1767–1774
- 135 Lonskaya, I., Hebrion, M.L., Desforges, N.M., Schachter, J.B. and Moussa, C.E. (2014) Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. *J. Mol. Med. (Berl.)* **92**, 373–386, <https://doi.org/10.1007/s00109-013-1112-3>
- 136 Reddy, P.H. and Oliver, D.M. (2019) Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease. *Cells* **8**, <https://doi.org/10.3390/cells8050488>
- 137 Boland, B., Kumar, A., Lee, S., Platt, F.M., Wegiel, J., Yu, W.H. et al. (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. *J. Neurosci.* **28**, 6926–6937, <https://doi.org/10.1523/JNEUROSCI.0800-08.2008>
- 138 Neely, K.M., Green, K.N. and LaFerla, F.M. (2011) Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ -secretase-independent manner. *J. Neurosci.* **31**, 2781–2791, <https://doi.org/10.1523/JNEUROSCI.5156-10.2010>
- 139 Shibuya, Y., Chang, C.C., Huang, L.H., Bryleva, E.Y. and Chang, T.Y. (2014) Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases A β 1–42 clearance. *J. Neurosci.* **34**, 14484–14501, <https://doi.org/10.1523/JNEUROSCI.2567-14.2014>
- 140 Shibuya, Y., Niu, Z., Bryleva, E.Y., Harris, B.T., Murphy, S.R., Kheirollah, A. et al. (2015) Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage. *Neurobiol. Aging* **36**, 2248–2259, <https://doi.org/10.1016/j.neurobiolaging.2015.04.002>
- 141 Lebedzinska, M., Duszynski, J., Rizzuto, R., Pinton, P. and Wieckowski, M.R. (2009) Age-related changes in levels of p66Shc and serine 36-phosphorylated p66Shc in organs and mouse tissues. *Arch. Biochem. Biophys.* **486**, 73–80, <https://doi.org/10.1016/j.abb.2009.03.007>
- 142 Lone, A., Harris, R.A., Singh, O., Betts, D.H. and Cumming, R.C. (2018) p66Shc activation promotes increased oxidative phosphorylation and renders CNS cells more vulnerable to amyloid beta toxicity. *Sci. Rep.* **8**, 17081, <https://doi.org/10.1038/s41598-018-35114-y>
- 143 Verfaillie, T., Rubio, N., Garg, A.D., Bultynck, G., Rizzuto, R., Decuyper, J.P. et al. (2012) PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. *Cell Death Differ.* **19**, 1880–1891, <https://doi.org/10.1038/cdd.2012.74>
- 144 Sharma, V., Ounallah-Saad, H., Chakraborty, D., Hleihil, M., Sood, R., Barrera, I. et al. (2018) Local Inhibition of PERK Enhances Memory and Reverses Age-Related Deterioration of Cognitive and Neuronal Properties. *J. Neurosci.* **38**, 648–658, <https://doi.org/10.1523/JNEUROSCI.0628-17.2017>
- 145 Area-Gomez, E. and Schon, E.A. (2017) Alzheimer Disease. *Adv. Exp. Med. Biol.* **997**, 149–156, https://doi.org/10.1007/978-981-10-4567-7_11
- 146 Schon, E.A. and Area-Gomez, E. (2013) Mitochondria-associated ER membranes in Alzheimer disease. *Mol. Cell. Neurosci.* **55**, 26–36, <https://doi.org/10.1016/j.mcn.2012.07.011>
- 147 Duce, J.A., Zhu, X., Jacobson, L.H. and Beart, P.M. (2019) Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine. *Br. J. Pharmacol.* **176**, 3409–3412, <https://doi.org/10.1111/bph.14767>
- 148 Wang, X. and Zheng, W. (2019) Ca²⁺ homeostasis dysregulation in Alzheimer's disease: a focus on plasma membrane and cell organelles. *FASEB J.* **33**, 6697–6712, <https://doi.org/10.1096/fj.201801751R>

- 149 Szymański, J., Janikiewicz, J., Michalska, B., Patalas-Krawczyk, P., Perrone, M., Ziolkowski, W. et al. (2017) Interaction of Mitochondria with the Endoplasmic Reticulum and Plasma Membrane in Calcium Homeostasis, Lipid Trafficking and Mitochondrial Structure. *Int. J. Mol. Sci.* **18**, <https://doi.org/10.3390/ijms18071576>